Bank of New York Mellon Corp Has $35.48 Million Position in The Chemours Company $CC

Bank of New York Mellon Corp lowered its holdings in The Chemours Company (NYSE:CC) by 3.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,610,298 shares of the specialty chemicals company’s stock after selling 53,992 shares during the period. Bank of New York Mellon Corp owned approximately 1.07% of Chemours worth $35,475,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of CC. Oregon Public Employees Retirement Fund boosted its holdings in shares of Chemours by 1.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 34,300 shares of the specialty chemicals company’s stock worth $404,000 after purchasing an additional 600 shares during the period. PFG Investments LLC grew its position in Chemours by 7.6% during the fourth quarter. PFG Investments LLC now owns 12,494 shares of the specialty chemicals company’s stock valued at $147,000 after purchasing an additional 883 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Chemours by 1.2% in the 4th quarter. State of Alaska Department of Revenue now owns 76,257 shares of the specialty chemicals company’s stock valued at $899,000 after buying an additional 932 shares during the period. Man Group plc increased its stake in Chemours by 0.4% in the 2nd quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock valued at $3,104,000 after buying an additional 979 shares during the period. Finally, Rothschild Investment LLC lifted its position in Chemours by 87.0% in the 4th quarter. Rothschild Investment LLC now owns 2,698 shares of the specialty chemicals company’s stock worth $32,000 after buying an additional 1,255 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Up 0.2%

Shares of CC stock opened at $17.25 on Monday. The stock’s 50 day simple moving average is $20.35 and its 200 day simple moving average is $19.92. The company has a debt-to-equity ratio of 18.98, a quick ratio of 0.87 and a current ratio of 1.82. The Chemours Company has a twelve month low of $10.44 and a twelve month high of $28.67. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -6.53 and a beta of 1.41.

Chemours (NYSE:CC) last announced its earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. Chemours had a positive return on equity of 52.49% and a negative net margin of 6.82%.The firm had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same quarter in the prior year, the business earned $0.13 earnings per share. The company’s revenue was up 1.0% on a year-over-year basis. As a group, research analysts predict that The Chemours Company will post 1.18 EPS for the current year.

Chemours Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Stockholders of record on Sunday, May 17th were given a $0.0875 dividend. This represents a $0.35 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is currently -13.26%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CC shares. Truist Financial lifted their target price on shares of Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Mizuho dropped their price target on shares of Chemours from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 1st. Morgan Stanley increased their price objective on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. UBS Group lifted their price objective on Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Chemours in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Chemours presently has an average rating of “Moderate Buy” and an average price target of $24.10.

Key Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Zacks Research upgraded Chemours (CC) from Hold to Strong Buy, signaling stronger confidence in the company’s outlook. 3 Stocks Worth Buying After Recent Broker Ratings Upgrade
• Positive Sentiment: Analysts also raised longer-term earnings forecasts, including FY2028 EPS to $2.38 from $2.36, suggesting better profit potential over time.
• Positive Sentiment: Zacks lifted its Q4 2027 EPS estimate to $0.53 from $0.50 and increased its Q2 2028 estimate to $0.61 from $0.60, reinforcing a more constructive view on future performance.
• Neutral Sentiment: Chemours announced it will release second-quarter 2026 results after the market closes on August 4, which keeps investors focused on the upcoming earnings report. Chemours Announces Dates for Second Quarter 2026 Earnings Release and Webcast Conference Call
• Negative Sentiment: Zacks trimmed its Q1 2027 EPS estimate to $0.39 from $0.41 and Q3 2027 to $0.56 from $0.57, showing that not all near-term expectations are improving.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.